Clinical trials: Bone Microarchitecture, active
Osteoporosis
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
Teriparatide (PTH) is the only bone formation therapy that has been approved for the treatment of postmenopausal osteoporosis in Canada.
- Trial name
- NCT01155232
- Testing
- Teriparatide
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Osteoporosis Risk, Bone Loss
Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies.
- Trial name
- MICROS (NCT06541548)
- Testing
- HR-pQCT, pQCT, DEXA
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Osteoporosis
Teriparatide (PTH) and Bone Strength in Postmenopausal Women
This study will investigate the effects on bone quality of a medication (Teriparatide) used to treat people with severe osteoporosis.
- Trial name
- NCT01155245
- Testing
- Forteo
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto